Log in

NASDAQ:REPHRecro Pharma Stock Price, Forecast & News

-0.27 (-5.64 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $4.52
50-Day Range
MA: $6.73
52-Week Range
Now: $4.52
Volume528,800 shs
Average Volume487,756 shs
Market Capitalization$106.52 million
P/E Ratio22.60
Dividend YieldN/A
Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. The company also develops early-stage product candidates, which include Dex-IN, an intranasal formulation of dexmedetomidine for use in clinical sedation; and two novel neuromuscular blocking agents and a related proprietary chemical reversal agent. In addition, it provides formulation and development services to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for commercial partners. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Read More
Recro Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:REPH



Sales & Book Value

Annual Sales$99.22 million
Cash Flow$0.57 per share
Book Value($0.30) per share


Net Income$-18,630,000.00


Market Cap$106.52 million
Next Earnings Date8/13/2020 (Estimated)

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

How has Recro Pharma's stock been impacted by COVID-19 (Coronavirus)?

Recro Pharma's stock was trading at $9.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPH shares have decreased by 50.7% and is now trading at $4.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Recro Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Recro Pharma.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Recro Pharma.

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) announced its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.30. The specialty pharmaceutical company earned $21.78 million during the quarter, compared to the consensus estimate of $19.40 million. Recro Pharma had a negative net margin of 25.38% and a negative return on equity of 15.25%. View Recro Pharma's earnings history.

What guidance has Recro Pharma issued on next quarter's earnings?

Recro Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-85 million, compared to the consensus revenue estimate of $98.26 million.

What price target have analysts set for REPH?

2 analysts have issued 1-year target prices for Recro Pharma's stock. Their forecasts range from $12.00 to $18.00. On average, they expect Recro Pharma's share price to reach $15.00 in the next year. This suggests a possible upside of 231.9% from the stock's current price. View analysts' price targets for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

News headlines about REPH stock have trended very positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Recro Pharma earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutRecro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,230,000 shares, an increase of 5.1% from the April 30th total of 1,170,000 shares. Based on an average daily trading volume, of 500,800 shares, the days-to-cover ratio is currently 2.5 days. Approximately 6.2% of the company's stock are short sold. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.72%), Federated Hermes Inc. (1.77%), State Street Corp (1.76%), Mak Capital One LLC (1.65%), Corsair Capital Management L.P. (1.56%) and Nuveen Asset Management LLC (1.55%). Company insiders that own Recro Pharma stock include Arnaud Ajdler and Geraldine Henwood. View institutional ownership trends for Recro Pharma.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Corsair Capital Management L.P., Two Sigma Investments LP, Driehaus Capital Management LLC, Parametric Portfolio Associates LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, JPMorgan Chase & Co., and Hillsdale Investment Management Inc.. View insider buying and selling activity for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was purchased by a variety of institutional investors in the last quarter, including Mak Capital One LLC, GW&K Investment Management LLC, Wells Fargo & Company MN, Roubaix Capital LLC, Nuveen Asset Management LLC, Private Advisors LLC, Two Sigma Advisers LP, and Deutsche Bank AG. View insider buying and selling activity for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $4.52.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $106.52 million and generates $99.22 million in revenue each year. The specialty pharmaceutical company earns $-18,630,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Recro Pharma employs 255 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.